Clinical Trial Info

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

Authored by

The experimental vaccine and placebo were both manufactured by Sinovac Research & Development Co., Ltd. A total of 422 subjects will be enrolled, with 72 at phase 1, and 350 at phase 2. Subjects will be assigned to receive two doses of different dosage of experimental vaccine or placebo on the schedule of day 0,28.